Part: 12         Session: 145678910111213141516171819202122         Page 732733734735736737738739740741742743744745746747748749750751752753754755756757758759760761762763764765766767768769770771772773774775776777778779780781782783784785786787788789790791792 of 999

-- to have this developed quickly. Now, of course, that will be a great struggle to get done quickly because -- however, it does have some commercial aspects, and I'm just hoping that some of the big pharmaceutical companies will try to develop it commercially because it would have to be used in every doctor's -- every hospital and in every major clinician's office, that treats cancer. If it got down to the kind of thing that you now have in testing whether or not one bacteria is responsive to penicillin or to streptomycin or 20 other antibiotics.

That's a very interesting angle that you mention, appealing to the commercialism of the manufacturers.

Oh, that's the only way you get anything done, because --

-- but this isn't understood by NIH, is it?

Oh, no they don't -- why, the NIH isn't the least bit interested in the success of any commerical venture. They're only interested in keeping what they're doing going. You know?

I know, but getting the commerical outfit to go ahead and do things, it's the sensible way in this --